Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

Sleep disruption appears to be a core component of Alzheimer's disease (AD) and its pathophysiology. Signature abnormalities of sleep emerge before clinical onset of AD. Moreover, insufficient sleep facilitates accumulation of amyloid-β (Aβ), potentially triggering earlier cognitive decline and...

Full description

Saved in:
Bibliographic Details
Published in:Trends in neurosciences (Regular ed.) 2016-08, Vol.39 (8), p.552-566
Main Authors: Mander, Bryce A, Winer, Joseph R, Jagust, William J, Walker, Matthew P
Format: Article
Language:English
Subjects:
aging
Aging - physiology
Alzheimer Disease - diagnosis
Alzheimer Disease - physiopathology
Alzheimer Disease - therapy
Alzheimer's disease
amyloid-β
Animals
BASIC BIOLOGICAL SCIENCES
Brain
cognitive decline
Eye movements
Humans
Medical treatment
Memory
Neurology
Neurosciences
Sleep
Sleep - drug effects
Sleep - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sleep disruption appears to be a core component of Alzheimer's disease (AD) and its pathophysiology. Signature abnormalities of sleep emerge before clinical onset of AD. Moreover, insufficient sleep facilitates accumulation of amyloid-β (Aβ), potentially triggering earlier cognitive decline and conversion to AD. Building on such findings, this review has four goals: evaluating (i) associations and plausible mechanisms linking non-rapid-eye-movement (NREM) sleep disruption, Aβ, and AD; (ii) a role for NREM sleep disruption as a novel factor linking cortical Aβ to impaired hippocampus-dependent memory consolidation; (iii) the potential diagnostic utility of NREM sleep disruption as a new biomarker of AD; and (iv) the possibility of sleep as a new treatment target in aging, affording preventative and therapeutic benefits.
ISSN:0166-2236
1878-108X
DOI:10.1016/j.tins.2016.05.002